Finally, the FAK inhibitor used in this study has passed the pharmacodynamic phase I dose-escalation trial in advanced solid tumors29, making this compound a viable candidate for future trials for diabetes treatment in humans. This evidence concerns the gene PTK2 and diabetes mellitus.